Mirmosayyeb Omid, Shaygannejad Vahid, Nehzat Nasim, Mohammadi Aida, Ghajarzadeh Mahsa
Isfahan Neurosciences Research Center, Isfahan University of medical sciences, Isfahan, Iran.
Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
Int J Prev Med. 2021 Feb 24;12:14. doi: 10.4103/ijpvm.IJPVM_75_20. eCollection 2021.
Seizure and epilepsy are among the initial symptoms of multiple sclerosis (MS), yet different prevalence rates are reported for them in the previous studies. The goal of this systematic review is to estimate the pooled prevalence of seizure and epilepsy in patients with MS.
We searched PubMed, Scopus, EMBASE, Web of Science, google scholar, and gray literature including references from identified studies and conference abstracts published up to October 2019. The search strategy included the MeSH terms and text words as ((Epilepsies OR Seizure Disorder OR Seizure Disorders OR Awakening Epilepsy OR Epilepsy, Awakening OR Epilepsy, Cryptogenic OR Cryptogenic Epilepsies OR Cryptogenic Epilepsy OR Epilepsies, Cryptogenic OR epilepsy OR seizure) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating).
The literature review resulted in 4860 articles; 2593 articles remained after eliminating the duplicates. For the final analysis, 39 articles were included, 9 of which were conference abstracts. The pooled prevalence of seizure in MS cases was 2%, 95% confidence interval (CI)(1%-3%) (I = 91.8%, < 0.001). The pooled prevalence of epilepsy in MS cases was 3%, 95% CI (2%-4%) (I2 = 92.9%, < 0.001). The pooled prevalence of epilepsy in Asia, Europe, and America was 6%, 3%, and 3%, respectively. The level of heterogeneity decreased after subgroup analysis in Asian and American subgroups. Meta-regression analysis showed continent is not a source of heterogeneity (coefficient = -0.007, = 0.6).
The result of this systematic review shows that the pooled prevalence of seizure and epilepsy among MS patients is 2% and 3%, respectively.
癫痫发作和癫痫是多发性硬化症（MS）的初始症状之一，但先前研究报道的其患病率有所不同。本系统评价的目的是估计MS患者中癫痫发作和癫痫的合并患病率。
我们检索了PubMed、Scopus、EMBASE、Web of Science、谷歌学术以及灰色文献，包括截至2019年10月发表的已识别研究的参考文献和会议摘要。检索策略包括医学主题词和文本词，即（（癫痫症或癫痫发作障碍或癫痫发作障碍或觉醒性癫痫或觉醒性癫痫症或隐源性癫痫或隐源性癫痫症或隐源性癫痫或隐源性癫痫症或癫痫症或癫痫发作）与（多发性硬化症或硬化症、多发性或播散性硬化症）或播散性硬化症）或MS（多发性硬化症））或急性暴发性多发性硬化症）。
文献综述共检索到4860篇文章；去除重复项后剩余2593篇文章。最终分析纳入39篇文章，其中9篇为会议摘要。MS病例中癫痫发作的合并患病率为2%，95%置信区间（CI）（1%-3%）（I² = 91.8%，P < 0.001）。MS病例中癫痫的合并患病率为3%，95%CI（2%-4%）（I² = 92.9%，P < 0.001）。亚洲、欧洲和美洲癫痫的合并患病率分别为6%、3%和3%。在亚洲和美洲亚组进行亚组分析后，异质性水平降低。Meta回归分析显示，大洲不是异质性的来源（系数 = -0.007，P = 0.6）。
本系统评价结果表明，MS患者中癫痫发作和癫痫的合并患病率分别为2%和3%。
Zotero 插件
